Replies to post #2865 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA corporate slide set (3/13/24):

https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4

There are no differences between the 3/13/24 slide set and the previous slide set on 2/7/24.

Clinical newsflow reiteration: ENTA expects to report data from the Zelicapavir RSVPEDs trial and the EDP-938 “challenge” trial in 3Q24. ENTA has not yet commented on when it will report data from the Zelicapavir PSVHR trial (for high-risk adults) because that depends on whether enrollment is completed during the current RSV season in the Northern Hemisphere.